Trial Profile
Interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma: Phase I/II Study.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 26 Jun 2013 ClinicalTrials.gov record NCT00006268 integrated.
- 26 Jun 2013 ClinicalTrials.gov record NCT00006268 integrated.
- 03 Jun 2011 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.